FDA OKs Wyeth's antidepressant Pristiq

Wyeth announced late Friday that it won FDA approval for Pristiq, its next-generation version of the antidepressant Effexor. Wyeth was looking for an approval of Pristiq to offset the considerable losses that are likely to follow Effexor's loss of patent protection in 2010. Pristiq is a norepinephrine reuptake inhibitor, as is Effexor. But researchers say the drug can be used in therapeutic doses from the day it is prescribed, as opposed to the steadily ascending doses that doctors currently prescribe Effexor.

The approval came with strings. Wyeth has to conduct a string of trials covering long-term maintenance, sexual dysfunction, pediatric studies and lower-dose studies.

- here's the release on the approval
- read the report from TheStreet

Related Articles:
Wyeth presents Pristiq data. Report
Wyeth's Pristiq shows benefits in clinical trial. Report
FDA issues approvable letter for Pristiq. Report
Wyeth expects provisional OK for Pristiq. Report

Suggested Articles

The duo will carry out a phase 2 study of BioNTech’s mRNA cancer immunotherapy in combination with Sanofi and Regeneron’s PD-1 blocker, Libtayo.

Merck was purposely cautious during the start of the pandemic when it came to vaccine development but is now slowly but surely ramping up its efforts

The money will equip AlloVir to embark on a broad clinical development program for a phase 3-ready cell therapy that targets five viruses.